Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology

about

Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology

Item

http://www.wikidata.org/entity/Q57495826

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Pharmacometric Applications an ...... Antibodies in Immuno-Oncology

@en

Pharmacometric Applications an ...... Antibodies in Immuno-Oncology

@nl

type

Item

label

Pharmacometric Applications an ...... Antibodies in Immuno-Oncology

@en

Pharmacometric Applications an ...... Antibodies in Immuno-Oncology

@nl

prefLabel

Pharmacometric Applications an ...... Antibodies in Immuno-Oncology

@en

Pharmacometric Applications an ...... Antibodies in Immuno-Oncology

@nl

P1476

Pharmacometric Applications an ...... Antibodies in Immuno-Oncology

@en

P2093

Lei Diao

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Oncology meets immunology: the cancer-immunity cycle.

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.

Concepts and challenges in quantitative pharmacology and model-based drug development.

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.

Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors.

Population pharmacokinetics of therapeutic monoclonal antibodies.

P2888

s40495-018-0142-5

P304

285-291

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40495-018-0142-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bernd Meibohm

P577

2018-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30319936

http://www.w3.org/2001/XMLSchema#string

P932

6181227

http://www.w3.org/2001/XMLSchema#string